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Non-alcoholic fatty liver disease comprises a spectrum of clinical and histopathological 
changes including ‘simple’ steatosis, steatosis with inflammation, steatohepatitis, cirrhosis 
and hepatocellular carcinoma. It was initially described in the context of drug-induced liver 
injury and acute liver disease following jejuno-ileal bypass surgery but since the early 1980s 
it has been widely acknowledged as the hepatic manifestations of the metabolic syndrome. It 
now represents a burgeoning public health crisis and is fast becoming the main indication for 
liver transplantation in some parts of the world. Its true incidence and prevalence is unknown 
although estimates have been made from large imaging studies. Liver biopsy interpretation 
is still regarded as the gold standard for making accurate diagnoses in NAFLD although 
sampling limitations are recognized. Furthermore, clear definitions for key histopathological 
components have been lacking and partly as a result of significant inter-observer variations 
in making a diagnosis of steatohepatitis. This review considers some aspects of 
classification and variant forms of NAFLD such as that occurring in children. It provides an 
update on grading and staging systems and histopathological prognostic factors and, finally, 
addresses the role of liver biopsy in contemporary clinical care of patients with NAFLD. 
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Introduction and historical perspective     
Alcoholic liver disease (ALD) is the archetypal fatty liver disease comprising a spectrum of 
pathological changes from the simple accumulation of lipid in hepatocytes (steatosis) 
through fat and inflammation (steatohepatitis) to cirrhosis and hepatocellular carcinoma1. 
That such a spectrum of disease could also be associated with other conditions was not 
widely acknowledged until the late 1970s when reports appeared of steatosis and 
steatohepatitis, histologically indistinguishable from that of alcoholic liver disease, occurring 
in patients following jejuno-ileal bypass surgery2, taking therapeutic agents such as 
perhexilene3 and in patients that were diabetic and obese4 Since then it is recognized that 
fatty liver disease (FLD) is a common phenomenon in patients with the metabolic syndrome. 
As with ALD there appear to be host factors that determine the degree (if any) of liver 
disease with some patients with BMIs greater than 40 showing no steatosis or 
steatohepatitis. Initially, it was considered that fatty liver disease in the metabolic syndrome 
was a more indolent process than in alcoholic liver disease with relatively slow progression 
but metabolically associated FLD is now one of the most common indications for orthotopic 
transplantation in many centres around the world. Increasingly it is also being seen as the 
underlying aetiology in the development of hepatocellular carcinoma where it may arise 
before cirrhosis is established.  
The incidence and prevalence of FLD has been assessed by a number of 
investigators but the true current and projected public health burden from this condition 
remains uncertain. The situation is confounded by inconsistent histopathological and clinical 
definitions for diagnosis and the existence of a number of semi-quantitative scoring systems 
to assess the extent of morphological damage. Furthermore there is often a lack of 
appreciation of the impact of co-morbid liver disease. This review focuses on the 
histopathology of non-alcoholic fatty liver disease (NAFLD) and addresses issues of 
classification and definitions particularly in the context of the metabolic syndrome. It also 




The first use of the term “fatty liver” in the English medical literature is attributed to 
Thomas Addison from Newcastle upon Tyne, England5, better known today for the 
description of the eponymous disease. Several years later, Karl Rokitansky, one of the 
forefathers of pathology from Vienna, Austria, observed in autopsy material that fat 
accumulation in the liver may be aetiologically related to cirrhosis6. Addison and Rokitansky 
most likely referred to alcoholic liver disease but an association of fatty liver with obesity and 
starvation was made by Bartholow in 18857 and by Statkewitsch in 18948, respectively. 
Pepper (1884)9 was first to describe fatty liver in a diabetic patient and in 1938 Charles 
Connor highlighted an aetiological link and described in detail FLD and its association with 
cirrhosis development in diabetics10. Thereafter, pathologists have recognized similarities 
between ALD and histological changes in the liver of diabetic and morbidly obese patients in 
a number of publications in the 1950s, 1960s and 1970s (summarized in Brunt et al 201211). 
Ludwig et al first used the term nonalcoholic steatohepatitis (NASH) in 1980 describing 20 
patients who did not misuse alcohol but had chronic progressive liver disease with 
histopathological features of ALD including steatosis, hepatocellular ballooning, Mallory-
Denk bodies (MDB) and zone 3 perisinusoidal/pericellular fibrosis. Since then, clinical and 
research interest in NAFLD has increased considerably with numerous studies documenting 
its heritability, highlighting the pathophysiological link with features of the metabolic 
syndrome (central obesity, insulin resistance or diabetes, dyslipidaemia, hypertension), 
focusing on non-invasive diagnosis of NASH, evaluating the natural history, and developing 
new pharmacological treatments12.   
 
Histopathological diagnosis of NAFLD/NASH in the setting of the metabolic syndrome 
Steatosis 
Hepatic steatosis refers to the accumulation of lipid droplets within hepatocytes and is 
considered pathological when it affects >5% of hepatocytes11. In adults, it usually first affects 
acinar zone 3 (centrilobular) hepatocytes, while in children zone 1 (periportal) predilection or 
a panacinar pattern is more common13. Morphologically, steatosis is classified as 
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macrovesicular, when a large lipid droplet (large droplet subtype) or several lipid droplets of 
variable size (small droplet subtype) occupy the cytoplasm and displace the nucleus and 
organelles to the cell periphery, and microvesicular, when the hepatocyte nucleus remains 
central and numerous minute lipid droplets, difficult to discern by light microscopy, fill the 
cytoplasm giving it a “foamy” appearance. Mixed steatosis, when both macrovesicular and 
microvesicular types co-exist, is common in NAFLD. In these cases, microvesicular steatosis 
is seen in small parenchymal patches with a non-zonal distribution and its presence 
correlates with increased steatosis severity and progressive disease14. Pure microvesicular 
steatosis, however, has not been reported in NAFLD to date although it may be diagnosed in 
alcoholics (so-called alcoholic foamy degeneration) where it may resemble the changes 
seen in Reye syndrome, acute fatty liver of pregnancy and drug toxicity15.  
 Lipid droplets are metabolically active and dynamic organelles composed of a central 
core of triacylglycerols and/or cholesterol esters and a peripheral single layer of 
phospholipids with associated proteins that belong to the perilipin/PAT family, including 
TIP47, MLDP, adipophilin and perilipin16. Recent studies have shown that during the 
formation of intracellular lipid droplets these proteins are expressed sequentially with TIP47- 
and MLDP-positive microvesicular steatosis evolving with time to adipophilin- and perilipin-
positive macrovesicular steatosis. The differences in PAT-proteins during lipid droplet 
evolution may underlie the different clinical significance of the two main types of steatosis 
and may aid the differentiation between acute and chronic steatosis17. The rs738409, I148M 
sequence polymorphism in patatin-like phospholipid domain containing protein (PNPLA3) 
has recently been seen to correlate with NAFLD development. The inactive PNPLA3 
accumulates on the surface of lipid droplets and is associated with an increase in 
macrovesicular steatosis18. In NAFLD, the accumulation of triacylglycerols within 
intracytoplasmic droplets may actually protect hepatocytes from the detrimental effect of 
non-droplet bound lipotoxic saturated free fatty acids19. 
 An important recent observation in NAFLD is that of reticulin loss, a finding more 
prominent in extensive steatosis and not related to the presence of inflammation or fibrosis20. 
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The pathophysiological effects of disruption of the connective tissue framework of the 
sinusoids remain to be determined. Steatosis may not persist as NAFLD progresses and 
may often be absent in cirrhotic specimens.  
Histological assessment of the extent of steatosis is usually semi-quantitative and is 
based on the percentage of hepatocyte involvement. Most commonly the affected 
parenchyma is divided in thirds i.e. 5-33%, 33-66%, >66% and consequently the severity of 
steatosis may be converted into mild, moderate or severe, respectively21,22. Histopathologists 
have a tendency to overestimate the extent of steatosis, especially when it is severe, 
therefore more accurate and objective methods for its quantitation have been devised mainly 
based on digital image analysis (DIA)23. It has been recently shown that the accuracy of 
microscopical fat estimation may be increased with the use of guideline images24. 
Conventional non-invasive imaging methods for assessing hepatic steatosis, such as 
ultrasound, computed tomography or magnetic resonance imaging (MRI), cannot detect 
relatively low amounts of hepatic fat (involving <30% hepatocytes) and therefore maybe 
inaccurate for NAFLD diagnosis. In contrast, novel imaging techniques, such as the 
ultrasound-based controlled attenuation parameter (CAP), MRI-estimated proton density fat 
fraction (PDFF), and 1H-magnetic resonance spectroscopy correlate well with histologically-
detected steatosis in both adult25 and paediatric NAFLD26. MRI, in particular, was shown to 
be more sensitive than liver histology in quantifying changes in hepatic fat27 and may prove 
useful for the non-invasive diagnosis of adult NAFLD in longitudinal natural history studies 
and therapeutic trials28.  
 
Steatosis and inflammation 
Steatosis in NAFLD only rarely is an “isolated” finding and is frequently accompanied by a 
chronic mononuclear cell inflammatory infiltrate of variable intensity located in the acini and 
composed of lymphocytes (mainly T cells), rare plasma cells, and monocytes. Mixed 
inflammation with neutrophils is less frequent while eosinophils are usually seen in relation to 
lipogranulomas (see below). Mild chronic or mixed portal inflammation may also be present. 
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Single ceroid-ladden PAS-diastase-positive Kupffer cells, solitary or in groups 
(microgranulomas), signpost previous inflammatory activity and may be seen diffusely in the 
acini. Lipogranulomas, composed of a central steatotic hepatocyte or fat droplet, an 
occasional eosinophil and peripheral collections of mononuclear cells and macrophages, are 
a frequent finding. Lipogranulomas are not indicative of active inflammation in NAFLD and 
are not included in the evaluation of necroinflammatory activity.  Kupffer cells are thought to 
play a significant role in NAFLD pathogenesis and progression by regulating hepatic 
triglyceride storage, mediating inflammation, contributing to hepatocyte injury and initiating 
fibrosis29,30. Their density in NAFLD correlates with necroinflammatory activity, progressive 
injury and the extent of fibrosis30. Abnormal innate immune signaling may trigger 
inflammation in NAFLD31 while oxidative stress can contribute to disease progression by 
stimulating both humoral and cellular immune responses32. 
 Studies on NAFLD pathogenesis have shown that inflammation is a driver for the 
development and progression of the disease30. Although, traditionally, steatosis or steatosis 
with inflammation were considered “innocent” and non-progressive, recent data from studies 
with paired liver biopsies have shown that both can progress to steatohepatitis with clinically 
significant fibrosis (albeit infrequently)33,34. 
 
Steatosis and fibrosis 
According to traditional definitions of NAFLD, hepatocellular injury and fibrosis, considered 
features of progression to steatohepatitis, are not observed in steatosis injury11,35. In adult 
NAFLD, mild fibrosis, either portal or zone 3 sinusoidal without hepatocellular injury may 
occasionally be encountered in cases of steatosis or steatosis with chronic inflammation. 
These cases possibly represent an intermediate stage in the dynamic process of NAFLD 
development and the presence of fibrosis could be indicative of prior episodes of active 
steatohepatitis. Sampling variability, discussed in more detail below, may also be 






It is important to draw a distinction between steatosis with mild inflammation and 
steatohepatitis. Most experts agree that the minimal requirements for the morphological 
diagnosis of NASH includes hepatocyte ballooning in addition to steatosis and 
inflammation36,37. These key lesions are typically accentuated in zone 3 of the hepatic 
acinus. Ballooned hepatocytes are characterized by a rounded shape and usually enlarged, 
lightly stained cytoplasm on routine histology (cellular diameter >30μm). The mechanisms 
underlying hepatocellular ballooning are not fully defined. However, oxidative stress-driven 
alterations of microtubules, loss of the intermediate filament cytoskeleton (which consists of 
keratins 8 and 18 (K8/18)), fluid retention, modification of small droplet fat and dilation of the 
endoplasmic reticulum are among the factors thought responsible38-42. Ballooning is an 
important component of all currently used grading systems of NAFLD activity (see below).  
 Morphological features frequently encountered but not necessary for the diagnosis of 
NASH are Mallory-Denk bodies (MDB), glycogenated nuclei in periportal hepatocytes, acinar 
lipogranulomas, megamitochondria, apoptotic hepatocytes and pericellular fibrosis36,37. MDB 
are frequently found in the cytoplasm of ballooned hepatocytes. They are irregularly formed 
hyaline proteinaceous inclusions consisting mainly of the intermediate filaments K8/18, the 
oxidative stress-induced 1/p62 sequestosome (p62) and ubiquitin43. Ballooned hepatocytes 
are often found in the vicinity of steatotic hepatocytes in zone 3 and are frequently 
surrounded by pericellular collagenous fibres (pericellular fibrosis). Hedgehog signalling 
(Shh) activated in ballooned hepatocytes and adjacent stromal cells may be one of the 
mechanisms responsible for increased pericellular matrix deposition44. 
 None of the single morphological features described above is specific for NASH (see 
below). Importantly, there is a very marked overlap of the morphological spectrum of NAFLD 
and ALD. Therefore, significant alcohol consumption has to be excluded in order to warrant 
a diagnosis of NASH. However, there is no universally accepted threshold that allows for the 
definition of excess alcohol consumption and indication that fatty liver disease in a given 
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patient is related to alcohol rather than insulin resistance. Data range between 10-20 g/day 
for women and 20-40 g/day for men45-49. Furthermore ALD and NAFLD share obesity and 
overweight as risk factors50,51. Both conditions can co-exist and aggravate liver injury52. The 
distinction between ASH and NASH may be very difficult or impossible on morphological 
grounds in an individual patient.  
The histological diagnosis of NASH has important clinical and prognostic 
implications. However, intra- and inter-observer variability in the interpretation of the 
morphological key features of NASH have been noted as important limitations of the utility of 
liver biopsy in assessing severity of disease35,53,54. In general, intra-observer variation is 
lower than inter-observer variation. While substantial agreement for steatosis was reported 
in two studies, the strength of inter-observer agreement for inflammation and ballooning 
were only fair to moderate22,55. However, it should be noted that substantial inter-observer 
agreement has been found in a more recent study56. There is some evidence that the use of 
immunohistochemistry may facilitate the identification of morphological features, reducing 
the level of inter-observer variation. This particularly applies to the detection and 
quantification of ballooning, a morphologically ill-defined feature of hepatocellular injury that 
may be discrete in mild NASH35 and that is also a feature of several liver diseases including 
acute and chronic viral and autoimmune hepatitis, chronic cholestasis, copper toxicity, and 
ischemia-reperfusion injury in the liver allograft. Significant diminution or loss of 
immunohistochemically demonstrable cytoplasmic expression of K8/1842 is only a feature in 
steatohepatitis, cholate stasis, copper toxicity and ischaemia-reperfusion injury.  Therefore, 
loss of cytoplasmic K8/18 immunohistochemical staining can be regarded a marker for a 
certain type of hepatocellular injury and is useful in objectively detecting ballooned cells with 
higher sensitivity than conventional H&E histology in NAFLD57. In addition, presence of small 
MDB is easily appreciated by p62 and ubiquitin immunohistochemistry58,59. The presence of 
MDB and expression of Shh in ballooned hepatocytes have been shown to correlate with 
severity of NASH and disease progression60,61. 
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Although initially considered a disease confined to affluent industrialised Western 
countries, obesity and insulin resistance are not restricted to the West and over the past two 
decades there has been a substantial increase in the prevalence of the metabolic syndrome 
in the Asia-Pacific region and developing nations in other continents62. Interestingly, only 
around 3% of Asians are classified as obese using a BMI cut-off of 30; it is recognised that 
obesity-related metabolic disorders occur at lower body weight than in Caucasians63. Some 
studies have estimated the incidence of NAFLD to be around 15% in China64 but extensive 
natural history studies are not available form that region. Despite the clinical differences 
between Western NAFLD and Asian NAFLD there is no current evidence to suggest that the 
histopathological features differ although to our knowledge this has not been 
comprehensively studied. 
 
Diagnosis of NAFLD/NASH in other disease settings 
Several therapeutic agents are known to be associated with liver injury resembling 
morphological changes typically occurring in NAFLD/NASH (termed chemotherapy- or drug-
associated steatohepatitis, CASH or DASH, respectively)65-67 and have the potential to 
progress to cirrhosis and portal hypertension68. The morphological features of drug- or 
chemotherapy-associated fatty liver disease broadly resemble that of metabolic syndrome-
associated NAFLD but their location within the hepatic acinus may differ from adult 
metabolic syndrome-associated NAFLD that has a zone 3 accentuation pattern of injury. For 
example, ballooned hepatocytes may occur in a periportal distribution in amiodarone-
induced hepatotoxicity. Moreover other drug-related changes including phospholipidosis or 
veno-occlusive disease69 may also be present along with features resembling NAFLD. While 
a large number of drugs can cause steatosis (reviewed in70), DASH/CASH is a relatively rare 
phenomenon. However, DASH/CASH due to amiodarone and irinotecan is well described71. 
Moreover, several steatogenic drugs such as tamoxifen, oestrogenic drugs and nifedipine 
may precipitate or exacerbate steatohepatitis in the presence of other risk factors. CASH in 
the setting of irinotecan treatment of liver metastases from colorectal cancer is associated 
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with an adverse prognosis66,72, particularly in patients with pre-existing liver damage72. Other 
causes of steatosis and steatohepatitis including those secondary to gastrointestinal bypass 
surgery, exogenous toxins and inherited metabolic disorders were reviewed by73. 
 
Criteria for diagnosing NAFLD/NASH with concurrent disease 
Given the high prevalence of NAFLD related to insulin resistance and/or the metabolic 
syndrome in Western populations, histological evidence of concurrent NAFLD and other liver 
disease, such as chronic hepatitis B (CHB) and C (CHC)74-76, human immunodeficiency virus 
(HIV) infection77, autoimmune hepatitis78-80, biliary disease81, 82 or inherited metabolic liver 
disease83 is a relatively frequent finding52,53,84,85. In some but not all liver diseases concurrent 
NAFLD appears to aggravate liver injury and fibrosis progression75-77,85,86. However, some 
diseases by themselves may be causally related to fatty liver development independently 
from insulin-resistance. Some of the more frequent ones include ALD, CHC, and drug 
induced liver injury (DILI). In such cases it is difficult to ascertain whether the concurrent 
condition leads to de novo steatosis or steatohepatitis or whether it exacerbates underlying 
NAFLD70, 87.  
 Fatty change of hepatocytes in CHC can be found in 40-86% of cases, depending on 
the viral genotype88. Steatosis in CHC cases may be due to virus-related insulin resistance 
or - in genotype 3 infections - to direct viral effects on hepatocellular lipid metabolism89. 
Acinar inflammation is frequently present in CHC. However, there is no convincing evidence 
that CHC per se can lead to the form of ballooning seen in steatohepatitis, accompanied by 
MDB formation and pericellular fibrosis. Therefore, the diagnosis of NASH in CHC, as well 
as in most other liver diseases, is reliably achieved by these findings, provided that ALD can 
be excluded on clinical grounds. In CHC, NASH preferentially develops in cases with severe 
steatosis, and genotype 3 infection independently from the metabolic syndrome90. 
Histological evidence of NAFLD in CHC90 has been associated with a higher fibrosis stage, 
impaired treatment response to interferons and ribavirin and an increased risk of HCC in 
most studies76,91. It is not yet clear whether fatty change and/or NASH impact on the efficacy 
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of newer protease-inhibitor based antiviral therapies49. NAFLD in CHB is associated with 
metabolic host factors and is not related to increased risk of fibrosis or acceleration of 
disease progression92,93. 
  Concurrence of ALD and NAFLD is probably not rare and is thought to promote liver 
injury and fibrogenesis. Although the spectrum of morphological lesions of ALD and NAFLD 
shows broad overlap94 there are several histological changes that occur in ALD-associated 
liver damage that have not been described in NAFLD and may thus serve as indicators that 
the FLD may be alcohol-related. These include obliterative lesions of the terminal hepatic 
venules, canalicular cholestasis, alcoholic foamy degeneration, marked portal and/or acinar 
infiltration by neutrophils, and marked ductular reaction and cholangiolitis35. 
 
Histological definitions and classification      
Although steatosis, steatosis with inflammation, NASH and cirrhotic NAFLD are considered 
components of a continuous spectrum, the initial concept of a two-hit phenomenon95 
whereby lipid accumulation is the first event in the pathogenesis of the disease while 
inflammatory mediators, endotoxin, mitochondrial dysfunction and ER stress represent a 
second stage which is a prerequisite for NASH development has recently been challenged.  
Many authorities now subscribe to a multiple, parallel-hit hypothesis96. Recent evidence 
suggests that free fatty acids (FFA) and their metabolites may be major factors in the 
pathogenesis of NASH97 and indeed there is evidence that triglyceride accumulation, the 
principal event in steatosis, by be a protective phenomenon as a sink for the more toxic 
FFA96. This has led some to believe that steatosis and steatohepatitis may not be parts of a 
linear spectrum of NAFLD but rather discrete entities98. Against this, however, are 
observations that NAFLD can regress either spontaneously or following therapeutic 
intervention and that in some cases there is not only a reduction in grade but even resolution 
of NASH35. 
Irrespective of whether the lesions are part of a continuum or distinct entities follow-
up studies (discussed below) underline the need for an accurate diagnosis of NASH. Central 
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to this is recognition of the presence of ballooning. In the absence of immunohistochemistry 
this relies on sometimes-subtle changes by microscopy with clarification of the cytoplasm of 
hepatocytes and accentuation of the cell borders. The inter-observer reproducibility of 
identifying ballooning among general pathologists is at best moderate but in our opinion this 
has been contributed to by imperfect definitions. While it has been said that balloons may 
come in all shapes and sizes, reproducibility is likely to be considerably improved if 
enlargement of the cell is considered a pre-requisite for the identification of ballooning. In our 
respective referral practices we have frequently encountered over-diagnosis of NASH in 
cases in which there has been steatosis and chronic inflammation but where cytoplasmic 
glycogenosis has been mistaken for ballooning. Some pathologists use the term borderline 
NASH to describe cases that fall into this category; we would discourage the use of this 
misleading term. 
Another area that requires further consideration is the definition of steatosis itself. In 
all recent scoring systems >5% is regarded as the cut-off for making a diagnosis. This 
however was based on early biochemical studies that indicated that normal liver contained 
5% lipid by weight reviewed by99. Adoption of this into histopathological definitions is 
somewhat arbitrary. A further pitfall is that not all papers have clearly defined whether it is 
5% of area containing fat or 5% of hepatocytes. A similar argument about arbitrary cut-off 
levels could be made for the definition of mild, moderate and severe steatosis.  
The NAFLD field has to some extent been plagued by the use of abundant terms and 
descriptors. Some authors have argued that non-alcoholic fatty liver disease is a misnomer 
and that it should be described using a positive criterion100. We agree with this and our 
preference in assessing biopsies from patients with fatty liver disease is to follow the 
approach taken in viral hepatitis which (i) to identify the principal lesion i.e. steatosis (+/- 
inflammation) or steatohepatitis (ii) if steatohepatitis, then include an assessment of grade 
and stage (see below) and (iii) description of the known aetiology when available. The latter 
we would suggest should be one of the following: alcoholic, metabolic, mixed 




Paediatric NAFLD       
NAFLD is the most common cause of steatosis in liver biopsies of children and adolescents 
followed by the effects of inherited metabolic disorders, cancer, and hepatitis C101. The 
increased prevalence of paediatric NAFLD (2.6%-7.1% in population-based studies and 
0.7%-17.3% in autopsy studies) reflects the increase in prevalence of overweight and 
obesity in children over the last two decades, and it is linked with the development of the 
metabolic syndrome and its consequences102. Genome-wide association studies (GWAS) 
have shown a correlation of the I148M PNPLA3 variant with NAFLD development in obese 
children of different ethnic backgrounds, as well as with histological severity of NASH and 
fibrosis (reviewed in102 and103). It is worrisome that radiological imaging may be normal in up 
to 1/3 of children with histologically proven NAFLD even in advanced disease stages101, and 
that significant histological changes may be detected in children with NAFLD and normal or 
mildly elevated aminotransferase levels104. This underlines the importance of liver biopsy in 
diagnosing paediatric NAFLD. NAFLD may advance to cirrhosis in 3%-5% of affected 
children73,101,104. Unfortunately, non-invasive methods for diagnosing progressed NAFLD with 
fibrosis in children (hepatic fibrosis scores, transient elastography etc.) are not yet fully 
developed for implementation in routine practice105. Binge alcohol drinking and its possible 
influence on underlying liver histology of obese teenagers is a cause of concern in 
adolescent NAFLD106.  
 Since the prototypic study of Schwimmer et al107 which highlighted histological 
differences between paediatric and adult NAFLD, several studies from different countries 
have confirmed that liver biopsies from children with NAFLD show more prominent portal-
based chronic inflammation and fibrosis; more severe steatosis (panacinar or with a zone 1 
predilection), less frequent hepatocyte ballooning and MDBs, and less commonly zone 3 
sinusoidal fibrosis108-110. Schwimmer et al first used the term “paediatric-type” or “type 2” 
NAFLD for this constellation of predominantly zone-1 based lesions in paediatric liver (51% 
of the 100 cases studied) in contrast to the less frequent (17%) zone-3 based histologic 
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pattern “adult type “ or “type 1” NAFLD. Type 2 NAFLD was thought to be more common in 
older boys of non-white ethnicity107. However, it was shown in subsequent studies that most 
cases (up to 82%) have overlapping features109. The National Institutes of Health (NIH)-
sponsored multicentre NASH Clinical Research Network (NASH CRN) proposed the use of 
terms “borderline zone 1” or “borderline zone 3” NAFLD when liver histology does not fulfil 
set criteria for NASH but shows intermittent features corresponding to accentuation of 
lesions in zone 1 (periportal) or zone 3 (around the terminal hepatic venule)111. Steatosis, 
portal inflammation, and fibrosis have been found to be less severe in NAFLD patients 
during or after puberty, compared to prepubertal cases, and postpubertal individuals had a 
lower prevalence of “borderline zone 1” NAFLD but more MDB112. Activation of hepatic 
progenitor cells in portal/periportal areas exhibiting high Hedgehog pathway activity and 
expressing adipocytokines may explain the portal-based histological patterns of injury and 
fibrosis in paediatric NAFLD113. Unfortunately, to date there are no widely accepted criteria to 
reach an undisputable diagnosis of “steatohepatitis” in paediatric NAFLD when non-adult 
histological patterns are seen. 
 Recently, a histological scoring system for grading activity in paediatric NAFLD has 
been developed and validated taking into account portal-based inflammation in addition to 
steatosis, acinar inflammation and ballooning114. The new score showed an excellent 
correlation with a global histological diagnosis NASH but its value in routine practice remains 
to be determined. 
 
Grading and staging of NAFLD 
Evaluation of morphological features of NAFLD by semi-quantitative scoring is frequently 
performed to provide global and standardized assessment of grade of disease activity and 
stage of fibrosis for use in clinical trials and to support of clinical decision making22,56,60,115,116. 
 One of the currently most widely used measures of grade, the NAFLD activity score 
(NAS)22, was developed by the NASH CRN117. This was based on a revision of the first 
grading system for NAFLD described by Brunt et al60. The NAS is derived from the sum of 
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semi-quantitative numerical scores applied to steatosis (0-3), hepatocellular ballooning (0-2) 
and acinar (lobular) inflammation (0-3) which can range from 0-8 (Table 1). At thresholds of 
<3 and ≥5 the NAS showed good correlation with the histological diagnoses not NASH and 
NASH, respectively (22). However, the sensitivity and specificity of the NAS for a histological 
diagnosis of NASH at a threshold level of ≥5 is 57% and 95%, respectively118. The NAS 
cannot therefore be used (and indeed was never intended) to replace the histopathological 
classification of NAFLD types (i.e. steatosis versus NASH). Instead, the NAS is designed for 
use in clinical trials to reflect changes in individual histological key features of NASH. 
Interestingly, in contrast to fibrosis stage, NAS did not correlate with prognosis (liver-related 
death) in a recent study115. The NAS system has been externally validated118 and is currently 
among the most widely used. The CRN also issued a scoring system for the evaluation of 
fibrosis stage22. As in chronic viral hepatitis scoring systems, fibrosis is assessed 
independently from grade119.  
 Recently, a simple histological algorithm based on a scoring system for NAFLD was 
developed by the European Fatty Liver Inhibition of Progression (FLIP) consortium in an 
attempt to standardize and limit inter-observer-related variation in the histological diagnosis 
of NASH (Table 1). The FLIP algorithm is based on semi-quantitative scoring of the key 
features of NASH, steatosis (S), activity (A), and fibrosis (F). Activity is reflected by the sum 
of scores for hepatocellular ballooning and acinar (lobular) inflammation. Fibrosis is 
assessed using a 5-tier scale broadly similar to the NASH CRN fibrosis score. The SAF 
scoring system was originally developed for grading and staging of NAFLD in patients with 
morbid obesity undergoing bariatric surgery116 but was subsequently applied to patients with 
metabolic syndrome-associated NAFLD56. The FLIP algorithm informed by the scores for 
steatosis, hepatocellular ballooning and inflammation allows for stratification into the two 
diagnostic categories: NASH versus steatosis. The diagnosis of NASH is only applied if all 
three key features, steatosis, hepatocellular ballooning and acinar inflammation are present. 
The SAF score was used to define two categories of NAFLD severity: mild disease when 
A<2 and/or F<2 and significant disease when A>2 and/or F>256. Disease severity is 
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therefore defined by hepatocellular ballooning, acinar inflammation and fibrosis, parameters 
of known prognostic significance in NAFLD. Steatosis, albeit a necessary component of 
NAFLD diagnosis but of only minor impact on prognosis remains a separate feature not 
included in this definition. The prognostic relevance of the dichotomous classification of mild 
and significant NAFLD remains to be evaluated in further studies. 
 Although not strictly a scoring system, one of the early morphological classification 
systems of NAFLD demonstrated the prognostic relevance of hepatocellular ballooning and 
fibrosis120. In the study of Matteoni et al, NAFLD was classified into four distinct types 
comprising fatty liver without inflammation (type 1) or with inflammation (type 2), and fatty 
liver with hepatocyte ballooning (type 3) or with ballooning and either MDB or fibrosis (type 
4). On long-term follow up in patients with types 3 and 4 NAFLD the prevalence of cirrhosis 
was 7-fold and liver-related death 5.5-fold higher than in patients with types 1 and 2 NAFLD. 
The prognostic utility of this simple morphological classification system of NAFLD and the 
prognostic impact of fibrosis stage was re-evaluated and confirmed in a recent study115.  
 However, several shortcomings inherent to any scoring system have to be 
considered. First, not all morphological features of injury can be accounted for. Several 
histological changes may provide important information with respect to prognosis (see 
below). Any scoring-based classification developed with simplicity and applicability in mind 
will not cover the whole range of complexity of the disease. Numeric score-based 
classification cannot therefore replace the descriptive interpretation of biopsy findings22,56. 
Secondly, interpretation of morphological features of NAFLD is prone to observer-related 
variation22,55,56. As noted above, this has been shown for some of the individual parameters 
of NAFLD scoring systems and is even more pronounced for the diagnosis of the different 
NAFLD types. In this respect the FLIP algorithm has been shown to significantly reduce the 
inter-observer bias of the diagnosis of NASH among expert hepatopathologists as well as for 
general pathologists trained in liver pathology56.  
 Despite efforts to ensure standardized and reproducible classification of NAFLD 
some observer-related bias will most likely remain. DIA allows for quantitative assessment of 
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morphological features in histological sections. Although investigated in more detail for 
CHC121,122, DIA could become a useful technique to overcome this obstacle in NAFLD. For 
example, DIA has been shown to unveil erroneous estimation of the extent of steatosis by 
conventional histology in NAFLD23,123. While several reports relate to the role of DIA for 
quantification of steatosis only few studies have addressed the impact of DIA-assisted 
quantification of fibrosis or inflammation on semi-quantitative scoring or correlation with non-
invasive methods like radiological fibrosis estimates and/or biochemical parameters/scores 
in NAFLD.  
 
Prognostic lesions in NAFLD/NASH 
Histological lesions of prognostic relevance 
Results from several studies have indicated that in patients with steatosis with or without 
inflammatory acinar changes, NAFLD will follow a benign course with low probability to 
progress to NASH and/or fibrosis124-126. However, as mentioned above, recently it has been 
shown that both steatosis and steatosis with inflammation can infrequently progress to 
steatohepatitis with clinically significant fibrosis33,34. 
 In contrast, histological NASH distinguished from steatosis with inflammation by the 
presence of hepatocellular ballooning has been shown to carry substantial potential for 
progression This is evident from the seminal work of Matteoni et al described above120. The 
prognostic relevance of this classification system was recently confirmed115. Furthermore, 
elevated mortality rates of NASH patients as compared to patients with steatosis were also 
reported by other investigators127,128. Portal inflammation in NAFLD is strongly associated 
with disease severity (fibrosis stage)129,130. 
 NASH is very frequently associated with fibrosis131. The fibrosis-promoting effect of 
NASH was confirmed in studies based on paired biopsies in which an increase of fibrosis 
stage over time was found in approximately 30-50% of NASH patients132-134 who may thus 
be at risk to develop cirrhosis. Indeed, as noted earlier, NASH is thought to represent one of 
the main causes of cryptogenic cirrhosis which is in most cases is considered burned-out 
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NASH135,136. There is evidence to suggest that cryptogenic cirrhosis and NASH-related 
cirrhosis are both risk factors for the development of HCC137,138. Recently, fibrosis was 
identified as the strongest predictor of overall and/or liver-related mortality in NAFLD115,139,140.  
 
Novel prognostic markers - clues from immunohistochemical and experimental studies 
Oxidative and ER-stress and apoptosis are among the most important mechanisms driving 
injury and inflammation leading to NASH which is implicated in increased inflammation and 
fibrogenesis as well as hepatocarcinogenesis via damage-associated molecular pattern 
molecules (DAMPs) and morphogens like Hedgehog and Wnt. Several factors involved in 
these pathways have been shown to exhibit altered expression in the liver of patients with 
NASH as well as in mouse models of NASH (reviewed in141).  
 For example, components of the inflammasome are overexpressed in livers of NASH 
patients as compared to controls142. As noted above, induction of Sonic hedgehog (Shh) 
expression in ballooned cells is accompanied by enhanced fibrogenesis via Shh signalling 
by neighbouring stromal cells44. Markers for hepatocellular ballooning may therefore be 
useful to identify these cells with higher sensitivity in individuals at risk for progressive 
disease. Furthermore, they may be helpful to detect and monitor treatment effects in clinical 
trials44,143. 
 Recently, the aldose reductase AKR1B10 was found to be highly differentially 
expressed in steatohepatitis compared to steatosis and normal liver144. AKR1B10 is involved 
in the detoxification of toxic aldehydes which may be prevalent in liver tissue in NASH or 
ASH. AKR1B10 was first described in human HCC145. It is expressed in several human 
cancers146 and may be involved in cell differentiation and proliferation147. AKR1B10 
expression may thus be a premalignant marker in the progression of steatohepatitis to HCC.  
 Increased numbers of CD68-positive macrophages in hepatic acini and portal tracts 
are found in NASH and advanced fibrosis130,148,149  An association with NASH and fibrosis 
was also noted for ductular reaction (DR) which is thought to represent expansion of  hepatic 
progenitor cell populations in response to injury. DR is a reactive lesion and consists of bile 
20 
 
ductules set in an inflamed stroma. DR may contribute to fibrogenesis and fibrosis 
progression in NAFLD. The extent of DR demonstrated by anti-keratin 7 antibodies has been 
shown to correlate with NASH and fibrosis stage150. Immunohistochemical or molecular 
markers of inflammatory activity, hepatocellular injury and fibrogenesis may be important 
indicators of higher risk of disease progression but their prognostic utility has not yet been 
evaluated in clinical studies. 
 
 
Liver biopsy in NAFLD – is there a role in 2015? 
A recent clinical definition of NAFLD requires (i) evidence of hepatic steatosis by histology or 
imaging and (ii) exclusion of other causes of fat accumulation in hepatocytes, such as 
significant alcohol consumption, hereditary disorders or steatogenic drugs49. The NAFLD 
spectrum is defined by morphological changes in the liver parenchyma discussed in detail 
above and carry increasingly adverse long-term prognosis ranging from no effects on overall 
survival for simple steatosis to increased mortality for NASH and cirrhosis mostly due to liver 
and/or cardiovascular disease120,151,152. Incidence and natural history of NAFLD are still not 
well defined because ethical and logistic reasons preclude the use of liver biopsy as a 
screening test. From non-invasive radiological studies (ultrasonography, magnetic 
resonance imaging) it is estimated that NAFLD is present in approximately 30% of 
Western153-155 and 15% of Asian-Pacific populations64,156 thus representing the one of the 
most common forms of liver disease141. However, in populations with metabolic risk factors 
such as diabetes mellitus or obesity the prevalence is higher (70-90%)157-162.  
 Simple steatosis alone affects the great majority of adult patients with NAFLD 124. A 
minority (10-30%) have NASH120,161,163, but this is the main progressive type of NAFLD 
associated with the development of fibrosis in 20-40% and cirrhosis in 20-30% of 
cases120,126,127,133,164 as well as significantly higher long-term mortality115,139. 
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 In adult patients with metabolic risk factors, in particular insulin resistance, clinical 
management is guided by the diagnosis/exclusion of NAFLD and discrimination of the 
NAFLD types. The diagnosis of NAFLD is based on the presence of hepatic steatosis which 
may be detected by imaging methods (e.g., ultrasound or MRI or novel techniques described 
above in the section of Steatosis)165 or histology after other causes of chronic liver disease 
and steatosis have been excluded. Since there are currently no clinical or routine 
biochemical factors available to detect NASH with sufficient diagnostic accuracy, histological 
evaluation is still considered the gold standard to monitor NAFLD patients and to identify 
NASH despite the limitations referred to earlier regarding sampling and inter-observer 
variation. However, given the high prevalence of NAFLD the use of liver biopsy as a 
diagnostic tool is considered problematic. Apart from logistic and economic considerations, 
liver biopsy is an invasive procedure and associated with a small but not negligible risk of 
morbidity and mortality. There has therefore been considerable effort applied to the 
development non-invasive methods for the discrimination of steatosis and NASH which has 
resulted in the description of an ever growing list of novel NASH biomarkers as well as 
clinical models166. The diagnostic accuracies of these markers for NASH diagnosis as 
indicated by the areas under the receiver–operating curve (AUROC) are in the range of 0.70 
to 0.90. Lack of external validation, standardized definitions of optimal cut-offs and 
availability are currently among the most important drawbacks precluding their use as stand-
alone tests in clinical practice166. Among the radiological methods, magnetic resonance 
elastography (MRE) may have good accuracy for the diagnosis of NASH167.  
Recent technical progress has also given rise to non-invasive tools to assess fibrosis 
stage in NAFLD patients with good accuracy. Scores and indices such as the NAFLD 
fibrosis score168,169 or the FIB-4 index and radiological methods, in particular transient 
elastography (TE) have been evaluated in different cohorts of NAFLD patients. These 
methods have been shown to reliably exclude lower fibrosis stages and have become widely 
accessible in clinical practice166,170.  
22 
 
Although new non-invasive techniques may eventually lead to a change in the role of 
liver biopsy, currently this is the definitive investigation for NAFLD providing at the same time 
information on steatosis, inflammation, hepatocellular injury, fibrosis, and concurrent liver 
disease. Most expert guidelines recommend liver biopsy for NAFLD patients at high risk for 
NASH and/or advanced fibrosis49,165,171,172. Histological predictors of fibrosis progression 
have been described in longitudinal studies with sequential biopsies127,173. Furthermore, it is 
not infrequent that NAFLD coexists with other liver diseases. In these settings clinical 
management is affected by potentially aggravated liver injury and accelerated disease 
progression50,85,174,175. Detection of NAFLD or NASH as a coexisting condition is therefore 
reliably achieved by histology84,176,177 and is recommended by the European guidelines on 
NAFLD/NASH48. In addition, most guidelines issued by international or national 
hepatological societies also consider the use of liver biopsy in suspected NAFLD patients in 
whom other causes of steatosis or chronic liver disease cannot be excluded on clinical 
grounds178. 
There is broad agreement that liver biopsy is an important tool in clinical trials and 
basic research on NAFLD defining the histological type of disease as well as assessing liver 
injury and effects of intervention37. However, despite the utility of histological evaluation for 
clinical and research applications the limitations mentioned earlier have to be taken into 
account. These include sampling and observer-related biases which can partly be overcome 
by taking biopsies of adequate length (at least 16 mm) and diameter (preferable use of a 16 
gauge or greater diameter needle) in similar fashion from the same liver lobe111, using 
standardized scoring systems for the interpretation of histopathological findings (described 
above) and/or DIA for quantitative assessment of histological features23,122,179. Besides 
histological evaluation, liver tissue analysis by immunohistochemistry and molecular 
methods has provided and is likely to continue to contribute importantly to the elucidation of 
mechanisms involved in pathogenesis and natural history of NAFLD (reviewed in53). 
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However, studies evaluating the potential of these factors for clinical decision-making are 
rare. 
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Figure 1. Expression of hepatocellular keratin 8 and 18 (K8/18) and sonic hedgehog (Shh) 
in steatohepatitis (A-D, serial sections, x100). (A) Ballooned hepatocytes with pale 
cytoplasm, few with small Mallory-Denk bodies (MDB, arrow-heads; haematoxylin & eosin, 
H&E) are surrounded by (B) collagen fibres (arrow-heads; chromotrope aniline blue, CAB). 
(C) The ballooned hepatocytes lack K8/18 immunostaining of the cytoplasm whereas the 
small MDB are K8/18-positive. (D) Ballooned hepatocytes are also decorated by antibodies 




Table 1: NASH Clinical Research Network (NASH CRN)22 and SAF116 histological scoring 
systems for NAFLD.        
NASH CRN SAF 










Hepatocyte Ballooning  0-2 Hepatocyte Ballooning  0-2 
0: None 
1: Mild, few 
2: Moderate-marked, many 
0: None 
1: Clusters of hepatocytes with       rounded 
shape and pale and/or reticulated 
cytoplasm 
2: Same as score 1 with enlarged 
hepatocytes (>2x normal size) 
     
Lobular (acinar) Inflammation 0-3 Lobular (acinar) Inflammation 0-2 
0: None 
1: <2  foci/20x field 
2: 2-4/20x field 
3:  >4/20x field 
0: None 
1:  2 foci per 20x field 
2: > 2 foci per 20x field 
NAFLD ACTIVITY SCORE (NAS): 0-8 ACTIVITY GRADE (A): 0-4 
Sum of scores for steatosis, ballooning and 
lobular inflammation 
Sum of scores for ballooning and lobular (acinar)  
inflammation  
A1 (A=1): mild activity  
A2 (A=2):moderate activity  
A3 & A4 (A>2): severe activity 
 
FIBROSIS STAGE  
0: No significant fibrosis 
1: 1a  mild (delicate) zone 3  
       perisinusoidal fibrosis (PSF) 
       (requires collagen stain to identify) 
   1b  moderate  (dense) zone 3 PSF  
   1c  portal fibrosis only 
2:  Zone 3 perisinusoidal fibrosis with periportal 
fibrosis 
3: Bridging fibrosis 
4: Cirrhosis 
FIBROSIS STAGE (F) 
F0: No significant fibrosis 
F1: 1a  mild zone 3 PSF 
      1b  moderate zone 3 PSF 
      1c  portal fibrosis only 
F2:  Zone 3 PSF with periportal fibrosis 
F3: Bridging fibrosis 
F4: Cirrhosis 
 
 SAF SCORE 
S0-3 A0-4 F0-4 
 
*percentage of parenchymal involvement by steatosis 
**percentage of hepatocytes containing large and/or medium-sized intracytoplasmic lipid 
droplets 
45 
 
 
 
